Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Chemotherapy. Stanford University School of Medicine, Stanford, CA, United States

Survival: 20.5 months
Toxicity Grade: 5
Treatments: Biologic therapy
Drugs: Leucovorin
Country: United States
City/State/Province: Stanford, CA
Hospital: Stanford University School of Medicine
Journal: Link
Date: 11/2008

Patients: This phase 2 study involved 45 patients with metastatic colorectal cancer. The median age was 57, ranging from 29 to 79 years of age. These patients had not received any previous treatment for their colorectal cancer.

Treatment: Patients were treated with the biological therapy gefitinib and the chemotherapy drugs 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4).

Toxicity: The most common grade 3 or 4 toxicities were diarrhea and neutropenia, occurring in 67% and 60% of patients, respectively. Other grade 3 or 4 toxicities included hypokalemia, nausea/vomiting, dehydration, and fatigue. One patient died from sepsis.

Results: The median overall survival was 20.5 months.

Support: This study was supported in part by research funds from AstraZeneca and Sanofi-Synthelabo. AstraZeneca markets gefitinib as Iressa and Sanofi markets oxaliplatin as Eloxatin.

Correspondence: Dr. Branimir Sikic

E-mail to a Friend Email Physician More Information